Refine by
Healthcare Decision Articles & Analysis
30 news found
With this strategic engagement, the companies will combine their healthcare datasets and delivery resources to offer bundled software and services solutions to healthcare companies and insurance companies in these markets. ...
” Other partners joining xCures in building this relationship with Aetion include AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women’s Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX, About Aetion Aetion is a ...
ByxCures
” “Understanding the impact of treatment decisions on outcomes for the over-65 population is of relevance to U.S. healthcare, as decisions made by the Centers for Medicare & Medicaid Services (CMS) regarding reimbursement, outcome-based incentives and penalties applied to health providers, and indication guidelines have enormous ...
“As precision medicine becomes the new standard of care, we are committed to continuous innovation to improve healthcare outcomes for early-stage breast cancer patients, clinicians and the healthcare ...
“The opening of this service will give more patients with advanced cancer access to blood-based biomarker testing and help their healthcare professionals make more informed treatment decisions,” said Helmy Eltoukhy, Guardant Health co-CEO. ...
In turn, this new information may help patients and their physicians to make more informed treatment decisions. About PreludeDx PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on ...
We interact with AI as seamlessly as we do our smartphones, through voice assistants, customer service, automated tasks, self-checkout, fraud detection, in healthcare decisions and infinitely more invisible applications that affect our daily lives. ...
” “We are excited to share this powerful data further demonstrating the applicability of DCISionRT to guide treatment decision for all DCIS patients,” says Dan Forche, President and CEO of ...
In turn, this new information may help patients and their physicians to make more informed treatment decisions. About PreludeDx PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on ...
The COPA is a novel, oral liquid dispensing system specifically designed to deliver accurate and precise doses of prescription medications only to a biometrically authenticated Intended User, with the goal of enhancing patient wellness by providing remote monitoring with advanced data analytics that are not dependent on patient self-reporting, allowing for improved adherence and informed medical ...
In turn, this new information may help patients and their physicians to make more informed treatment decisions. About PreludeDx PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on ...
Women want to know that the latest technology is supporting their healthcare teams, and they want to select imaging centers and hospital systems that give them that confidence. With women making up to 80% of all healthcare decisions for themselves and their entire family, this year’s focus on AI and Women's Health is more important than ...
Signifier Medical Technologies LLC, a Boston-based medical technology company, announced today that the Centers for Medicare & Medicaid Services (CMS) established two new Level II Healthcare Common Procedure Coding System (HCPCS) codes to describe eXciteOSA, the first-ever FDA authorized de-novo device for daytime treatment of mild obstructive sleep apnea (OSA) and primary ...
"The perspectives shared through this survey by people living with bipolar I disorder underscore the need for effective medications and the importance of considering the unique needs and experiences of individuals living with this disease – whether physical, mental or social – as people work with their healthcare providers to evaluate treatment options." Key findings ...
ByAlkermes
Background & Objective: why did we develop SURUS? Every day, healthcare professionals use scientific evidence to make decisions, like which dose to give to a patient or which brand of medicine to offer. ...
In turn, this new information may help patients and their physicians to make more informed treatment decisions. About PreludeDx PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on ...
"The ability to determine the extent and location of recurrent prostate cancer, in conjunction with other available clinical information, can inform the management plan for men with recurrent disease. Informed decision-making can facilitate personalized patient management. ADT is commonly used to treat recurrent prostate cancer, but may produce undesirable side effects for many ...
“Exo’s hardware and software were designed in tandem, with the future of decentralized healthcare at the forefront of every decision,” said Exo CEO Sandeep Akkaraju. “Our vision is a healthcare system unconstrained by the four walls of a hospital and engineered for a world where providers can see clearly into every patient ...
ByExo
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an analysis highlighting that Bladder EpiCheck® can reduce both patient burden and healthcare system costs in the U.S. and European countries for low grade intermediate risk non-muscle ...
Each of the chosen companies will receive high-profile visibility to health care investors, stakeholders and decision-makers, as well as customized mentorship through one-on-one matching with corporate partners to help with commercialization throughout Asia Pacific. ...